Novartis bags first EMR in India

 The drug makers that are likely to be hit directly by the development include Natco, Sun Pharmaceuticals, Ranbaxy, Cipla, Intas and Camlin Pharma who have already launched a form of this drug. Novartis will enjoy five years of exclusive marketing right for the drug from the date of approval.

 Ranjit Shahani, vice-chairman and managing director Novartis India said,